Cullinan Common Stock vs Total Assets Analysis
| CGEM Stock | USD 16.42 0.95 5.47% |
Cullinan Oncology financial indicator trend analysis is way more than just evaluating Cullinan Oncology LLC prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cullinan Oncology LLC is a good investment. Please check the relationship between Cullinan Oncology Common Stock and its Total Assets accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cullinan Oncology LLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.
Common Stock vs Total Assets
Common Stock vs Total Assets Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cullinan Oncology LLC Common Stock account and Total Assets. At this time, the significance of the direction appears to have strong contrarian relationship.
The correlation between Cullinan Oncology's Common Stock and Total Assets is -0.53. Overlapping area represents the amount of variation of Common Stock that can explain the historical movement of Total Assets in the same time period over historical financial statements of Cullinan Oncology LLC, assuming nothing else is changed. The correlation between historical values of Cullinan Oncology's Common Stock and Total Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock of Cullinan Oncology LLC are associated (or correlated) with its Total Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Assets has no effect on the direction of Common Stock i.e., Cullinan Oncology's Common Stock and Total Assets go up and down completely randomly.
Correlation Coefficient | -0.53 |
| Relationship Direction | Negative |
| Relationship Strength | Very Weak |
Common Stock
Total Assets
Total assets refers to the total amount of Cullinan Oncology assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Cullinan Oncology LLC books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Most indicators from Cullinan Oncology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cullinan Oncology LLC current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cullinan Oncology LLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. As of the 26th of June 2024, Selling General Administrative is likely to grow to about 44.6 M, though Tax Provision is likely to grow to (13.4 M).
| 2023 | 2024 (projected) | Non Recurring | 183.9K | 97.2K | Research Development | 148.2M | 155.6M |
Cullinan Oncology fundamental ratios Correlations
Click cells to compare fundamentals
Cullinan Oncology Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Cullinan Oncology fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 100.5M | 214.7M | 437.2M | 561.1M | 485.1M | 509.4M | |
| Total Current Liabilities | 2.5M | 14.3M | 11.7M | 22.5M | 28.1M | 29.5M | |
| Accounts Payable | 934K | 9.7M | 3.2M | 2.7M | 2.5M | 2.0M | |
| Other Current Assets | 1.5M | 2.1M | 6.1M | 7.2M | 13.1M | 13.8M | |
| Total Liab | 140.4M | 291.0M | 11.8M | 26.1M | 31.2M | 56.0M | |
| Total Stockholder Equity | (40.8M) | (77.6M) | 422.6M | 535.0M | 453.7M | 476.4M | |
| Net Tangible Assets | (40.8M) | (77.6M) | 425.0M | 535.0M | 615.3M | 646.0M | |
| Retained Earnings | (41.5M) | (93.3M) | (158.9M) | (47.7M) | (200.9M) | (190.8M) | |
| Cash | 63.3M | 168.2M | 430.9M | 550.1M | 98.4M | 147.9M | |
| Total Current Assets | 100.1M | 212.3M | 296.6M | 474.5M | 480.2M | 504.2M | |
| Other Current Liab | 1.6M | 4.6M | 8.6M | 18.2M | 24.2M | 25.4M | |
| Property Plant And Equipment Net | 182K | 130K | 77K | 5.3M | 3.5M | 3.7M | |
| Net Debt | (63.3M) | (168.2M) | (430.9M) | (544.9M) | (94.8M) | (99.6M) | |
| Non Current Assets Total | 370K | 2.4M | 140.6M | 86.6M | 4.9M | 4.7M | |
| Cash And Short Term Investments | 98.6M | 210.2M | 430.9M | 550.1M | 467.1M | 328.3M | |
| Short Term Investments | 35.4M | 42.0M | 230.7M | 311.1M | 368.6M | 387.1M | |
| Liabilities And Stockholders Equity | 100.5M | 214.7M | 434.8M | 561.1M | 485.1M | 335.6M | |
| Non Current Liabilities Total | 137.8M | 276.7M | 65K | 3.6M | 3.1M | 2.9M | |
| Other Stockholder Equity | (137.0M) | (261.0M) | 582.3M | 585.3M | 654.7M | 687.4M | |
| Net Invested Capital | (40.8M) | (77.6M) | 425.0M | 535.2M | 453.7M | 233.7M | |
| Property Plant And Equipment Gross | 182K | 130K | 309K | 5.4M | 3.9M | 4.1M | |
| Accumulated Other Comprehensive Income | (4K) | (2K) | (838K) | (2.6M) | (129K) | (135.5K) | |
| Net Working Capital | 97.6M | 198.0M | 284.8M | 452.0M | 452.1M | 278.2M | |
| Property Plant Equipment | 182K | 130K | 77K | 1.2M | 1.4M | 1.4M |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Cullinan Oncology LLC using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Additional Information and Resources on Investing in Cullinan Stock
When determining whether Cullinan Oncology LLC is a strong investment it is important to analyze Cullinan Oncology's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cullinan Oncology's future performance. For an informed investment choice regarding Cullinan Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cullinan Oncology LLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cullinan Oncology. If investors know Cullinan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cullinan Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.13) | Return On Assets (0.22) | Return On Equity (0.29) |
The market value of Cullinan Oncology LLC is measured differently than its book value, which is the value of Cullinan that is recorded on the company's balance sheet. Investors also form their own opinion of Cullinan Oncology's value that differs from its market value or its book value, called intrinsic value, which is Cullinan Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cullinan Oncology's market value can be influenced by many factors that don't directly affect Cullinan Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cullinan Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cullinan Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cullinan Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.